|
|||||
![]() |
|
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
“Rosnilimab’s Phase 2b data in rheumatoid arthritis (RA) delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that is durable for at least three months off-drug. The strength of the data, as well as positive feedback from the KOL community, gives us confidence in the transformational potential of rosnilimab. With enrollment completed in the Phase 2 ulcerative colitis (UC) trial, we look forward to reading out top-line data through Week 12 in Q4 2025, as well as potential additional six- and 12-month data from this trial in 2026,” said Daniel Faga, president and chief executive officer of Anaptys. “Additionally, we are excited to announce the initial indication for our CD122 antagonist, ANB033, is celiac disease (CeD), a serious autoimmune disease triggered by the ingestion of gluten, affecting more than 2.1 million people in the U.S. but with no approved therapies. We believe ANB033’s MoA, inhibiting both IL-2 and IL-15 signaling, is well-suited to target the multiple pathogenic drivers of CeD. We plan to initiate a Phase 1b cohort by Q4 2025 and will discuss the program in depth at a dedicated R&D event later this year.”
PORTFOLIO UPDATES
Rosnilimab (Pathogenic T Cell Depleter)
ANB033 (CD122 antagonist)
ANB101 (BDCA2 modulator)
COLLABORATION UPDATES
GSK Immuno-Oncology Financial Collaboration
Vanda Imsidolimab Financial Collaboration
FINANCIAL UPDATES
Stock Repurchase Program and Cash Runway
Second Quarter 2025 Financial Results
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s top-line Phase 2 clinical trial data in ulcerative colitis; whether positive clinical trial results in rosnilimab’s Phase 2b clinical trial in rheumatoid arthritis increases the likelihood of getting positive results from rosnilimab’s Phase 2 clinical trial in ulcerative colitis; timing of the R&D event for ANB033; timing of the initiation of the ANB033 phase 1b cohort in celiac disease; the potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement; the potential to receive any additional milestones and royalties from the GSK collaboration and the timing therefor; and the Company's projected cash runway. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
AnaptysBio, Inc. Consolidated Balance Sheets (in thousands, except par value data) (unaudited) | |||||||
June 30, 2025 | December 31, 2024 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 44,298 | $ | 123,080 | |||
Receivables from collaborative partners | 21,418 | 40,765 | |||||
Short-term investments | 221,412 | 262,293 | |||||
Prepaid expenses and other current assets | 4,778 | 5,738 | |||||
Total current assets | 291,906 | 431,876 | |||||
Property and equipment, net | 1,628 | 1,849 | |||||
Operating lease right-of-use assets | 13,464 | 14,383 | |||||
Long-term investments | 27,996 | 35,470 | |||||
Other long-term assets | 256 | 256 | |||||
Total assets | $ | 335,250 | $ | 483,834 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 3,329 | $ | 4,002 | |||
Accrued expenses | 30,197 | 39,501 | |||||
Current portion of operating lease liability | 2,001 | 1,925 | |||||
Total current liabilities | 35,527 | 45,428 | |||||
Liability related to sale of future royalties | 331,361 | 353,426 | |||||
Operating lease liability, net of current portion | 13,095 | 14,112 | |||||
Stockholders’ equity: | |||||||
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June 30, 2025 and December 31, 2024, respectively | — | — | |||||
Common stock, $0.001 par value, 500,000 shares authorized, 27,973 shares and 30,473 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 28 | 30 | |||||
Additional paid in capital | 792,531 | 829,860 | |||||
Accumulated other comprehensive (loss) gain | (6 | ) | 305 | ||||
Accumulated deficit | (837,286 | ) | (759,327 | ) | |||
Total stockholders’ (deficit) equity | (44,733 | ) | 70,868 | ||||
Total liabilities and stockholders’ equity | $ | 335,250 | $ | 483,834 |
AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data) (unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Collaboration revenue | $ | 22,263 | $ | 10,971 | $ | 50,034 | $ | 18,150 | |||||||
Operating expenses: | |||||||||||||||
Research and development | 37,824 | 41,997 | 79,004 | 79,039 | |||||||||||
General and administrative | 10,609 | 9,295 | 24,739 | 21,633 | |||||||||||
Total operating expenses | 48,433 | 51,292 | 103,743 | 100,672 | |||||||||||
Loss from operations | (26,170 | ) | (40,321 | ) | (53,709 | ) | (82,522 | ) | |||||||
Other income (expense), net: | |||||||||||||||
Interest income | 3,654 | 4,623 | 8,067 | 9,207 | |||||||||||
Non-cash interest expense for the sale of future royalties | (19,606 | ) | (10,953 | ) | (37,667 | ) | (17,270 | ) | |||||||
Other income (expense), net | 3,531 | — | 5,433 | (2 | ) | ||||||||||
Total other expense, net | (12,421 | ) | (6,330 | ) | (24,167 | ) | (8,065 | ) | |||||||
Loss before income taxes | (38,591 | ) | (46,651 | ) | (77,876 | ) | (90,587 | ) | |||||||
Provision for income taxes | (39 | ) | (9 | ) | (83 | ) | (9 | ) | |||||||
Net loss | (38,630 | ) | (46,660 | ) | (77,959 | ) | (90,596 | ) | |||||||
Unrealized (loss) gain on available for sale securities | (167 | ) | 209 | (311 | ) | 382 | |||||||||
Comprehensive loss | $ | (38,797 | ) | $ | (46,451 | ) | $ | (78,270 | ) | $ | (90,214 | ) | |||
Net loss per common share: | |||||||||||||||
Basic and diluted | $ | (1.34 | ) | $ | (1.71 | ) | $ | (2.62 | ) | $ | (3.35 | ) | |||
Weighted-average number of shares outstanding: | |||||||||||||||
Basic and diluted | 28,810 | 27,356 | 29,722 | 27,079 |
Aug-06 | |
Aug-06 | |
Jul-29 | |
Jun-03 | |
May-27 | |
May-12 | |
May-05 | |
May-05 | |
Apr-17 | |
Mar-25 | |
Mar-24 | |
Mar-16 | |
Feb-27 | |
Feb-27 | |
Feb-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite